These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35447297)

  • 1. Strategies of engineering nanomedicines for tumor retention.
    Qian X; Xu X; Wu Y; Wang J; Li J; Chen S; Wen J; Li Y; Zhang Z
    J Control Release; 2022 Jun; 346():193-211. PubMed ID: 35447297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating tumor mechanics with nanomedicine for cancer therapy.
    Zhao Q; Chen J; Zhang Z; Xiao C; Zeng H; Xu C; Yang X; Li Z
    Biomater Sci; 2023 Jun; 11(13):4471-4489. PubMed ID: 37221958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosting antitumor efficacy of nanoparticles by modulating tumor mechanical microenvironment.
    Zhang X; Zhang X; Yong T; Gan L; Yang X
    EBioMedicine; 2024 Jul; 105():105200. PubMed ID: 38876044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aptamer-guided nanomedicines for anticancer drug delivery.
    Alshaer W; Hillaireau H; Fattal E
    Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrier permeation and improved nanomedicine delivery in tumor microenvironments.
    Liu J; Zhang J; Gao Y; Jiang Y; Guan Z; Xie Y; Hu J; Chen J
    Cancer Lett; 2023 May; 562():216166. PubMed ID: 37028698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-based combination nanomedicines for cancer therapy.
    Li Y; Lin W
    Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy.
    Xu X; Wu Y; Qian X; Wang Y; Wang J; Li J; Li Y; Zhang Z
    Adv Healthc Mater; 2022 Jan; 11(1):e2101428. PubMed ID: 34706400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
    Qin M; Xia H; Xu W; Chen B; Wang Y
    Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DePEGylation strategies to increase cancer nanomedicine efficacy.
    Kong L; Campbell F; Kros A
    Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
    Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
    Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcytosis-enabled active extravasation of tumor nanomedicine.
    Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
    Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced nanomedicines for the regulation of cancer metabolism.
    Yang J; Zhao Y; Zhou Y; Wei X; Wang H; Si N; Yang J; Zhao Q; Bian B; Zhao H
    Biomaterials; 2022 Jul; 286():121565. PubMed ID: 35576808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine.
    Tian Y; Cheng T; Sun F; Zhou Y; Yuan C; Guo Z; Wang Z
    Adv Colloid Interface Sci; 2024 Apr; 326():103124. PubMed ID: 38461766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced permeability and retention effect-focused tumor-targeted nanomedicines: latest trends, obstacles and future perspective.
    Shekhar S; Chauhan M; Sonali ; Yadav B; Dutt R; Hu L; Muthu MS; Singh RP
    Nanomedicine (Lond); 2022 Aug; 17(18):1213-1216. PubMed ID: 36136592
    [No Abstract]   [Full Text] [Related]  

  • 20. Nanomedicines for cancer therapy: current status, challenges and future prospects.
    Bor G; Mat Azmi ID; Yaghmur A
    Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.